Early Treatment Response of Bupropion SR in Smoking Cessation according to Genetic Polymorphism and Temperamental Characteristics.
- Author:
Young Sik LEE
1
;
Sung Yeop KIM
;
Doug Hyun HAN
;
Kyung Joon MIN
;
Chul NA
Author Information
1. Department of Neuropsychiatry, ChungAng University School of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Bupropion;
Smoking cessation;
Genetic polymorphism;
Temperamental characteristics
- MeSH:
Alleles;
Bupropion*;
Dopamine Plasma Membrane Transport Proteins;
Genotype;
Homozygote;
Humans;
Male;
Nicotine;
Norepinephrine Plasma Membrane Transport Proteins;
Polymorphism, Genetic*;
Serotonin Plasma Membrane Transport Proteins;
Smoke*;
Smoking Cessation*;
Smoking*;
Temperament*;
Volunteers
- From:Korean Journal of Psychopharmacology
2006;17(2):219-228
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Bupropion is an antidepressant with proven efficacy for smoking cessation, however the response rate is some limited. With this background, the authors investigated the difference of early bupropion response in smoking cessation according to individual genetic polymorphism and temperamental characteristics. METHOD: Subjects were 113 Korean male volunteers who were nicotine dependent and wanted to quit smoking. Authors compared 6 candidate genes (DRD2, DRD4, dopamine transporter, norepinephrine transporter, serotonin transporter, COMT), and Temperament Character Inventory (TCI) between response group and non-response group after 3 weeks bupropion treatment. RESULT: Among 6 candidate genes, DRD2 homozygotes (A2/A2+A1/A1), COMT H/H genotype and H allele carriers showed high rate of smoking cessation by bupropion. NET-8 GG genotype and G allele carriers showed low rate of smoking cessation by bupropion. Persistence score in TCI was significant between two groups. CONCLUSION: DRD2, COMT, NET-8 genetic polymorphisms and some temperamental characteristics could predict success of smoking cessation by early treatment response of bupropion.
